 LEXINGTON, Mass., Aug. 02, 2021 GLOBE NEWSWIRE -- Keros Therapeutics, Inc. Keros Nasdaq: KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the appointment of Simon Cooper, M.B.B.S, as Keros Chief Medical Officer, effective as of August 2, 2021. 